Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Study Identifier
190342-035
CT.gov Identifier
NCT01229462
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Other
  • Ocular Hypertension
    • Study Drug
  • brimonidine tartrate/timolol fixed combination ophthalmic solution
  • brimonidine tartrate ophthalmic solution
  • timolol ophthalmic solution
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 75 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Open-angle glaucoma or ocular hypertension in at least one eye that is not responsive to topical beta blockers * No anticipated wearing of contact lenses during study
    Exclusion Criteria:
    * Active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye) * Any intraocular surgery or laser (eg, cataract surgery or Lasik) within 3 months * Required regular use of other ocular medications except for occasional use of artificial tears

    Protocol Summary

    This study will evaluate the safety and efficacy of brimonidine tartrate/timolol fixed combination (Combigan®) compared with brimonidine tartrate (Alphagan®) and timolol in patients with glaucoma or ocular hypertension who do not respond well to topical beta blockers.

    Study Locations

    Location
    Status
    Location
    Guangzhou, Guangdong, China
    Status
    Not applicable